New Multi-Mission Beechcraft King Air Demonstrator Unveiled at Paris Air Show
16.6.2025 09:30:00 EEST | Business Wire | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced its new multi-mission Beechcraft King Air demonstration aircraft will be making its show and European debut at the 2025 Paris Air Show. The aircraft is equipped to showcase a wide range of missions available on the versatile and reliable Beechcraft King Air platform, and will be on static display Monday, June 16, through Thursday, June 19, at the Textron Pavilion A2.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615940392/en/
From Wichita, Kansas to Paris, France: Beechcraft King Air demonstrator makes international debut
“The King Air’s acquisition and operation cost, combined with excellent speed, range and payload capacity make it an excellent value for a wide range of special missions,” said Bob Gibbs, vice president, Special Missions Sales. “The best-selling turboprop serves as an ideal platform for intelligence, surveillance and reconnaissance, utility transport, training and more. Over the last few years, we have seen solid European demand of our Cargo Door King Air 360C for essential air ambulance services.”
Endless Special Missions Possibilities on Display
When government, military and commercial customers want airborne solutions for critical missions, they turn to Textron Aviation. The Beechcraft King Air on display is fitted with extended range (ER) fuel tanks, a factory-installed extended utility nose capable of housing a variety of sensors up to a 20-inch EO/IR sensor and a lift kit to retract, factory-installed wing hardpoint provisions and a cargo door that supports air ambulance and freight operations to enhance mission flexibility.
Powered by PT6A-67A engines with dual oil coolers, the aircraft offers hot/high airfield performance as well as impressive climb performance and cruising speeds.
Interior features include a mission rack with displays and a mission computer, Original Equipment Manufacturer (OEM) VIP seating, AvFab and LifePort mission seats and a LifePort medevac stretcher. The cockpit is compatible with Night Vision Imaging Systems (NVIS).
King Air Leadership
More than 7,800 Beechcraft King Air turboprops have been delivered to customers since 1964, making it the best-selling business turboprop family in the world. The fleet has surpassed 66 million flight hours in its 60 years, serving roles in all branches of the U.S. military and flying both commercial and special missions.
Textron Aviation returns to the Paris Air Show as the industry leader with more than 1,700 Cessna and Beechcraft turbine aircraft in Europe and more than 255,000 aircraft delivered worldwide. In France, nearly 200 Cessna and Beechcraft turbine aircraft support a wide variety of missions for commercial, government and military customers.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops, and high-performance pistons, to special missions, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable, productive and flexible flight.
For more information, visit www.txtav.com| specialmissions.txtav.com| defense.txtav.com| scorpion.txtav.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO, and Textron Systems.
For more information, visit: www.textron.com.
Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to our ability to keep pace with our competitors in the introduction of new products and upgrades with features and technologies desired by our customers; volatility in the global economy or changes in worldwide political or macroeconomic conditions that adversely impact demand for our products; and risks related to our international business, including establishing and maintaining facilities in locations around the world and relying on joint venture partners, subcontractors, suppliers, representatives, consultants and other business partners in connection with international business, including in emerging market countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250615940392/en/
Contacts
Media:
Doug Scott
+1.316.347.0116
dscott2@txtav.com
txtav.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.txtav.com%2
F&esheet=54272237&newsitemid=20250615940392&lan=en-US&anchor=txtav.com&index=9&m
d5=29b9edb2b979f0b89309d23c56f89397
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom